Finance Watch: $1.32bn In New Biopharma VC Financings As Year-End Approaches

Year-End Flurry Of Deals In Full Swing

Private Company Edition: In recent weeks, 19 companies disclosed venture capital funding of $20m or more, including FogPharma with a $178m series D round and Apogee’s $169m launch. Also, Avalon BioVentures spun out of Avalon Ventures with a $135m fund.

Finance Watch Private Company
• Source: Shutterstock

The end of each year brings a surge in venture capital funding announcements as biopharmaceutical companies and investors seek to close as many deals as possible before everyone takes off for the December holidays, and 2023 is no different from any other year. During the three weeks starting 21 November and ending 9 December, 19 drug developers announced VC financings of $20m or more totaling $1.32bn.

Topping the list of recent VC deals were three companies with mega-rounds of more than $100m each – FogPharma...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Financing

Aurigene Oncology CEO On Biotech Valuations, CAR-Ts And Reimbursement Models

 

Aurigene Oncology CEO talks in this audio interview about the tough biotech funding environment, pipeline assets including a CAR-T therapy in Phase II, "hybrid" manufacturing, outcome-based reimbursement and the promise of bispecifics and multispecifics, including Akeso's PD-1/VEGF bispecific.

Finance Watch: Just As The XBI Began Turnaround, Trump Upped MFN Pricing Threats

 
• By 

Public Company Edition: The XBI fund attempted a correction midway through the week ending Aug. 1, but President Trump’s most favored nation drug pricing threats tanked valuations again. In financings, Leads Biolabs raised $189m in a Hong Kong IPO and Abivax closed a $747.5m FOPO.

Metabolic Disease-Focused Poxel Teeters On The Edge

 

The Lyon, France-based company has filed for insolvency and is running out of time to find new funding for its metabolic disease pipeline.

Frazier Life Sciences Raises $1.3bn To Fund Start-Ups Through Value-Creating Data

 
• By 

Frazier Life Sciences will invest 40%-50% of its new venture capital fund in new biopharma companies financed to develop preclinical drug candidates through clinical proof of concept and, hopefully, M&A.

More from Business

Competition Weighs On Gilead’s CAR-Ts As Both See Sales Decline

 

The quarter saw strong growth overall, but the company now expects sales of Yescarta and Tecartus to fall for the full year 2025 versus 2024 thanks to competition.

More Players, Better Pricing, Tough Equity Market: Royalty Deals Go Mainstream

 
• By 

Royalty deals are on track for another blowout year, but it’s not only because of a depressed biotech market. Large investment firms such as KKR are taking note.

50% Levy On India And Brazil, US Tariffs Leave Global Trade, Forecasts In Disarray

 
• By 

50% tariffs on US imports from India, a range on others, an uncertain outcome of Section 232 investigations of pharma and talk of BRICS tariffs are making forecasting for the pharma industry extremely difficult, Scrip finds in this infographic analysis